A retrospective review of data reveals frequency of recurrent immune-mediated diarrhea and colitis with resumption of ICI therapy after an initial adverse event.
Ibrutinib may impair natural killer cell cytotoxic activity, potentially through off-target inhibition of IL-2–inducible kinase (ITK), an in vitro study suggests.
New research has linked microsatellite instability and the number of insertion/deletion mutations present in a tumor to clinical response to checkpoint inhibition.
An MYD88 mutation, protein expression, and PD-1/PD-L1 expression were not associated with survival in primary central nervous system lymphoma.
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
A prospective study sought to determine the antibody response of pneumococcal vaccines in patients with multiple myeloma.
The primary end point of the study is the percentage of patients achieving a major pathological response.
The reintroduction of FOLFOXIRI/bev in the progressive setting may provide a further benefit in mCRC.
Researchers from the FDA analyzed 10 RCTs conducted in patients with unresectable or metastatic melanoma who were treated with 1 of 3 drug types.
An FDA analysis of pooled data identified potential factors associated with unexplained early mortality in immunotherapy arms of clinical trials.
